Mural Oncology Plc Announces Acquisition Agreement

Mural Oncology Plc ( (MURA) ) just unveiled an announcement.

On August 20, 2025, Mural Oncology plc entered into a Transaction Agreement with XOMA Royalty Corporation’s subsidiary, XRA 5 Corp., for the acquisition of Mural’s entire share capital. The acquisition, valued at approximately $36.2 million, offers Mural shareholders a base cash price of $2.035 per share, with a potential additional cash amount of up to $0.205 per share, contingent on Mural’s closing net cash exceeding estimated figures. The acquisition, subject to shareholder and High Court approval, is expected to close by the end of 2025, marking a strategic move supported by Mural’s Board to maximize shareholder value.

The most recent analyst rating on (MURA) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on Mural Oncology Plc stock, see the MURA Stock Forecast page.

Spark’s Take on MURA Stock

According to Spark, TipRanks’ AI Analyst, MURA is a Neutral.

Mural Oncology Plc’s stock is weighed down by its financial challenges, including zero revenue and high cash burn, which significantly impact its overall score. Technical indicators suggest some positive momentum, but the stock faces resistance. Valuation remains unattractive due to unprofitability. However, upcoming clinical milestones and strategic focus on efficiency provide potential upside, reflected in the corporate events score.

To see Spark’s full report on MURA stock, click here.

More about Mural Oncology Plc

Mural Oncology plc is a biotechnology company focused on developing cytokine-based immunotherapies for cancer treatment using its protein engineering platform. The company aims to provide meaningful clinical benefits to cancer patients.

Average Trading Volume: 155,708

Technical Sentiment Signal: Strong Sell

Current Market Cap: $31.53M

Find detailed analytics on MURA stock on TipRanks’ Stock Analysis page.